Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.

Abstract

Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur). Complete or partial deficiency of DPD activity has been demonstrated to induce severe toxicities in cancer patients treated with fluoropyrimidine therapy. We analyzed 180 individuals that were candidates… (More)
DOI: 10.1007/s11739-013-0936-8

Topics

2 Figures and Tables

Cite this paper

@article{Magnani2013FluoropyrimidineTI, title={Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.}, author={Elena Magnani and Enrico Farnetti and Davide Nicoli and B. Casali and Luisa Savoldi and Chiara Focaccetti and Corrado Boni and Adriana Albini and Maria Chiara Banzi}, journal={Internal and emergency medicine}, year={2013}, volume={8 5}, pages={417-23} }